OncoMatch/Clinical Trials/NCT05141253
Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors
Is NCT05141253 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies RD133 for cancer.
Treatment: RD133 — This study is a single-center exploratory clinical trial. It is estimated that 9-24 subjects will be enrolled. The "3+3" dose escalation design is adopted. The main purpose is to evaluate the safety of RD133 in the treatment of subjects with relapsed or refractory MSLN-positive solid tumors and explore the Recommend phase II dose of RD133 in the treatment of patients with relapsed/refractory MSLN-positive solid tumors.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: MSLN overexpression (>25% positive rate on tumor cell membrane)
>25% Mesothelin positive rate on tumor cell membrane confirmed by prior immunohistochemistry of tumor tissue or freshly punctured tissue
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: gene therapy
Subject who has received gene therapy before enrollment
Cannot have received: systematic immunosuppressive therapy
Exception: except topical drugs
Subject who needs systematic immunosuppressive therapy (except topical drugs) to control autoimmune diseases
Cannot have received: live vaccines
Subject who has been injected with live vaccines within 4 weeks before enrollment
Cannot have received: other interventional clinical research drugs
Subject has received other interventional clinical research drugs within 12 weeks before apheresis
Lab requirements
Blood counts
Neutrophils≥1.0×10^9/L (no G-CSF within 7 days); Platelet count ≥75×10^9/L (no transfusion/TPO within 7 days); Hemoglobin ≥9g/dl (no transfusion within 7 days)
Kidney function
Creatinine clearance rate ≥60 ml/min
Liver function
Bilirubin value ≤1.5×ULN (except bile duct obstruction caused by tumor compression); ALT or AST≤2.5×ULN (with liver involvement ≤5×ULN)
Cardiac function
Echocardiography: ejection fraction ≥50%, without obvious pericardial effusion
subject must have proper organ function and meet all of the following criteria: ... see full criteria
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify